Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GONAL-F RFF vs CHORIONIC GONADOTROPIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular growth and maturation and spermatogenesis.
Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.
Induction of ovulation in anovulatory women,Controlled ovarian hyperstimulation for assisted reproductive technologies,Spermatogenesis induction in hypogonadotropic hypogonadism (with h CG)
FDA-approved: Induction of ovulation in infertile females (as part of controlled ovarian hyperstimulation),FDA-approved: Treatment of prepubertal cryptorchidism,FDA-approved: Treatment of hypogonadotropic hypogonadism in males,Off-label: Weight loss (not recommended),Off-label: In vitro fertilization protocols
Subcutaneous injection, initially 75-150 IU once daily for 5-7 days for ovulation induction. For controlled ovarian hyperstimulation, 75-300 IU once daily starting day 2 or 3 of cycle. Dose adjusted based on response.
For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.
Terminal elimination half-life: approximately 24-30 hours (range 24-36 h) following subcutaneous administration; supports once-daily dosing regimen.
Biphasic: initial half-life ~11 hours, terminal half-life ~23–30 hours. Single-dose half-life ~32 hours; repeated dosing may extend due to accumulation.
Primarily hepatic via proteolytic degradation and renal clearance
Primarily metabolized in the liver via proteolytic degradation; undergoes renal excretion with a half-life of 24-36 hours.
Renal excretion: approximately 70% of the dose is eliminated in urine as intact hormone and metabolites; fecal excretion is negligible (<5%).
Primarily renal; intact h CG is excreted in urine. Negligible biliary/fecal elimination.
Approximately 95% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG).
Approximately 80% bound; binds to albumin and sex hormone-binding globulin (SHBG) with low affinity.
Volume of distribution: 6-10 L/kg, indicating extensive distribution into extracellular fluid and tissues (e.g., ovaries).
0.3–0.5 L/kg; distributes into extracellular fluid, gonadal tissues, and poorly into fat.
Subcutaneous: approximately 70-80% (relative to intravenous administration); intramuscular: 100% (absolute bioavailability for Gonal-f RFF not explicitly reported, but similar to follitropin alfa).
IM/SC: ~40% to 100% (mean ~78%) due to variable absorption; IV: 100% (not typical). Oral: negligible (<1% due to degradation).
No specific dose adjustment provided by manufacturer. GFR <30 m L/min: use with caution due to limited data.
No specific dose adjustment guidelines available; use with caution in severe renal impairment (GFR <30 m L/min/1.73 m²).
No specific dose adjustment provided by manufacturer. Child-Pugh Class C: use with caution; no established guidelines.
No specific dose adjustment guidelines available; use with caution in severe hepatic impairment (Child-Pugh class C).
Not indicated for use in pediatric patients. Safety and efficacy not established.
Cryptorchidism: 500-1000 IU subcutaneously or intramuscularly 2-3 times per week for 6 weeks. Delayed puberty: 500-1500 IU subcutaneously or intramuscularly 2-3 times per week.
Not indicated for use in geriatric patients. Safety and efficacy not established.
No specific dose adjustments; monitor for fluid retention and cardiovascular effects.
None
None. However, use in females requires careful monitoring to avoid ovarian hyperstimulation syndrome (OHSS), which can be severe.
Ovarian hyperstimulation syndrome (OHSS),Ovarian torsion,Multiple pregnancy,Pulmonary embolism and thromboembolic events,Ovarian enlargement,Ectopic pregnancy,Congenital malformations (risk similar to general population)
Ovarian hyperstimulation syndrome (OHSS): Risk of severe OHSS with ascites, pleural effusion, and thromboembolic events,Multiple pregnancy: Increased risk due to ovulation induction,Thromboembolic events: Increased risk, especially in patients with prior history,Ovarian enlargement: Monitor with ultrasound,Hormonal-dependent malignancies: Caution in patients with prior history
Hypersensitivity to FSH or any excipients,High levels of FSH indicating primary gonadal failure,Uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary),Sex hormone dependent tumors (ovarian, breast, uterus, testis, hypothalamus, pituitary),Abnormal uterine bleeding of undetermined origin,Pregnancy and lactation
Pregnancy,Primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Active thromboembolic disorder,Hormone-sensitive tumors (e.g., prostate, breast, ovarian),Hypersensitivity to h CG or any component
No significant food interactions. Maintain a balanced diet; avoid excessive alcohol intake as it may impair fertility. Caffeine in moderation (≤200 mg/day) is generally acceptable, but discuss with your healthcare provider.
No known food interactions.
Fetal risk cannot be ruled out. Category X: contraindicated in pregnancy due to risk of multiple gestation and ectopic pregnancy; no systematic evidence of teratogenicity but animal studies show post-implantation loss and fetal abnormalities at high doses.
Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies has been established. However, use during pregnancy is contraindicated except as part of assisted reproductive technology protocols where its role is physiological. No fetal risks documented from therapeutic use in second or third trimester.
No human data; M/P ratio unknown. Excretion in breast milk unknown; caution advised due to potential for serious adverse effects in infant.
Chorionic gonadotropin is not orally bioavailable and is likely degraded in infant gastrointestinal tract. Excretion into breast milk is unknown; M/P ratio not established. However, due to its protein nature, transfer is expected to be minimal. Use during breastfeeding is not recommended unless clearly necessary; theoretical risk of hormonal effects on infant.
Contraindicated in pregnancy; no dosing adjustments applicable as therapy is discontinued upon confirmed pregnancy.
No pharmacokinetic dose adjustments are recommended in pregnancy as the drug is typically administered only prior to conception or in early pregnancy for luteal phase support. The endogenous hormone levels in pregnancy far exceed exogenous doses. No dose modification required in later trimesters because use is contraindicated.
GONAL-F RFF (follitropin alfa) is a recombinant follicle-stimulating hormone (FSH) used for ovulation induction and controlled ovarian hyperstimulation. Administer subcutaneously; rotate injection sites to prevent lipodystrophy. Adjust dose based on ovarian response monitoring (ultrasound and estradiol levels). Risk of ovarian hyperstimulation syndrome (OHSS) requires vigilance; withhold h CG if estradiol >3000 pg/m L or >20 follicles ≥14 mm. Use with Gn RH agonist or antagonist to prevent premature LH surge. Prefilled syringe ensures accurate dosing; do not mix with other drugs. Store refrigerated, but may be stored at room temperature (≤25°C) for up to 28 days.
Chorionic gonadotropin (h CG) is used to trigger ovulation in assisted reproduction and to treat hypogonadotropic hypogonadism in males. Monitor for ovarian hyperstimulation syndrome (OHSS) in women; discontinue if severe. Do not use in women with primary ovarian failure. In males, may cause gynecomastia or fluid retention.
Inject exactly as prescribed, preferably at the same time daily.,Rotate injection sites (abdomen, thigh) to avoid lumps or pain.,Do not skip doses; contact your doctor if you miss a dose.,Report symptoms of OHSS: severe pelvic pain, bloating, nausea, rapid weight gain, or decreased urination.,Avoid pregnancy tests until instructed, as the medication may cause false results.,Store unopened vials in the refrigerator. Once opened, use within 28 days if kept at room temperature.
Report abdominal pain, bloating, nausea, vomiting, or rapid weight gain (signs of OHSS).,In males, report breast tenderness or swelling, or fluid retention (swollen ankles/feet).,Do not use if pregnant or breastfeeding unless directed by a specialist.,For fertility: timing of intercourse or IUI is critical; follow cycle monitoring closely.,In males: take as prescribed for testicular descent or hypogonadism; may require multiple doses.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GONAL-F RFF vs CHORIONIC GONADOTROPIN, answered by our medical review team.
GONAL-F RFF is a Gonadotropin that works by Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular growth and maturation and spermatogenesis.. CHORIONIC GONADOTROPIN is a Gonadotropin Hormone that works by Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GONAL-F RFF and CHORIONIC GONADOTROPIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GONAL-F RFF is: Subcutaneous injection, initially 75-150 IU once daily for 5-7 days for ovulation induction. For controlled ovarian hyperstimulation, 75-300 IU once daily starting day 2 or 3 of cycle. Dose adjusted based on response.. The standard adult dose of CHORIONIC GONADOTROPIN is: For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GONAL-F RFF and CHORIONIC GONADOTROPIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GONAL-F RFF is classified as Category C. Fetal risk cannot be ruled out. Category X: contraindicated in pregnancy due to risk of multiple gestation and ectopic pregnancy; no systematic evidence of teratogenicity but anima. CHORIONIC GONADOTROPIN is classified as Category C. Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.